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Objective. Respiratory depression is a serious and potentially life-threatening side-effect of opioid
therapy. The objective of this investigation was to characterize the relationship between buprenorphine
or fentanyl exposure and the effectiveness and safety outcome in rats.
Methods. Data on the time course of the antinociceptive and respiratory depressant effect were analyzed
on the basis of population logistic regression PK–PD models using non-linear mixed effects modeling
software (NONMEM). The pharmacokinetics of buprenorphine and fentanyl were described by a three-
and two-compartment model, respectively. A logistic regression model (linear logit model) was used to
characterize the relationship between drug exposure and the binary effectiveness and safety outcome.
Results. For buprenorphine, the odds ratios (OR) were 28.5 (95% CI, 6.9–50.1) and 2.10 (95% CI, 0.71–
3.49) for the antinociceptive and respiratory depressant effect, respectively. For fentanyl these odds
ratios were 3.03 (95% CI, 1.87–4.21) and 2.54 (95% CI, 1.26–3.82), respectively.
Conclusion. The calculated safety index (ORantinociception/ORrespiratory depression) for fentanyl of 1.20
suggests that fentanyl has a low safety margin, implicating that fentanyl needs to be titrated with caution.
For buprenorphine the safety index is 13.54 suggesting that buprenorphine is a relatively safe opioid.
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INTRODUCTION
Worldwide millions of people suffer from severe (un-
controlled) and sometimes incurable pain and are dependent
on the daily intake of analgesic drugs to relief their pain.
Opioidanalgesicsareamongthemosteffectiveagentscurrently
available for treating postoperative and chronic (malignant)
pain. Apart from their analgesic actions, all opiates produce
side-effects (1,2). Although most of these side effects are mild
in nature and have little clinical relevance, respiratory
depression is a potentially life-threatening complication of
opiate therapy (3,4). Therefore, careful titration of the opioid
dose to the desired analgesic effect is essential to avoid
respiratory depression (5). This applies particularly to potent
opioid analgesics.
Fentanyl is a m-opioid agonist which is frequently used
both in anesthesia and for the treatment of acute and chronic
pain (6–8). In pharmacological terms, fentanyl is a high-
efficacy full agonist at the m-opioid receptor with steep
concentration–response curves (9,10). Due to the relatively
narrow therapeutic window of fentanyl the risk of severe fatal
respiratory depression is rather large. As a result fentanyl
dosing needs to be carefully titrated to the optimal analgesic
effect (11). To facilitate fentanyl dosing, advanced drug
delivery systems, aiming at an improved selectivity of action
have been introduced. Slow release preparations and trans-
dermal patches for opiates are examples of drug delivery
systems which have been developed with the aim to optimize
opiate delivery and to reduced side-effects (12).
Another approach towards the reduction of side effects
is the use of compounds with a more favorable effectiveness–
safety balance. In this respect it is of interest that in theory,
partial agonists can have a greater selectivity of action than
full agonists (13). Considering the potential lethality of
opioid-induced respiratory depression, partial agonists at
the m-opioid receptor provide potential advantages over full
agonists, in terms of the effectiveness–safety balance for the
treatment of pain. Buprenorphine is a semi-synthetic opioid,
which has been in clinical use for the treatment of acute and
chronic pain since 1979 (14). Recently, it has been demon-
strated that buprenorphine behaves as a partial agonist with
respect to respiratory depression both in rats (15) and in
humans (16), consistent with its partial agonistic behavior in
in vitro bio-assays (17). An important consequence of the
observed Fceiling effect_ is that an overdose of buprenorphine
is less likely to cause severe and potentially life-threatening
respiratory depression. Interestingly, for the antinociceptive
effect, buprenorphine displays no ceiling effect in the same
concentration range in which maximum respiratory depres-
sion is elicited, indicating that within the therapeutic concen-
tration range buprenorphine acts as a full agonist with regard
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expression in the distinct brain tissues can explain why
buprenorphine behaves as partial agonist for one effect
(respiratory depression, in brain tissue with no receptor
reserve) and as a full agonist for another effect (antinocicep-
tion, in brain tissue with receptor reserve; 20).
The objective of this study was to characterize the effec-
tiveness and safety of buprenorphine and fentanyl in rats
using non-linear mixed effects logistic regression analysis.
Therapeutic utility functions (21–24) were constructed to
assess the effectiveness/safety balances of buprenorphine and
fentanyl.
MATERIALS AND METHODS
Animal data for the PK–PD analysis of the safety and
effectiveness of buprenorphine and fentanyl were obtained
from two previously published studies on the PK–PD relation-
ships of buprenorphine and fentanyl for the antinociceptive
(18) and respiratory depressant effect (15). The protocols of
the investigations were approved by the Ethical Committee
on Animal Experimentation of Leiden University.
Briefly, the experimental details of the investigations
were as follows. Male Wistar rats (Charles River BV, Zeist,
The Netherlands), weighting initially 225–250 g, were used in
the studies. Two days before the start of the experiment,
indwellingcannulaewereimplantedintherightfemoralartery
for the serial collection of blood samples and in the right
jugular vein for drug administration. Surgical procedures were
performed under anesthesia with an intramuscular injection of
0.1 mg/kg medetomide hydrochloride (Domitor, 1 mg/ml,
Pfizer, Capelle a/d IJssel, The Netherlands) and 1 mg/kg
Ketamine base (Ketalar 50 mg/ml, Parke-Davis, Hoofddorp,
The Netherlands).
Different doses of buprenorphine (0.025 to 0.1 mg/kg)
and fentanyl (0.015–0.04 mg/kg) were tested to characterize
the concentration–antinociceptive effect relationships. For
respiratorydepression,buprenorphineandfentanylweretested
in the dose ranges 0.025–0.3 mg/kg and 0.03–0.085 mg/kg,
respectively. Buprenorphine and fentanyl were administered
via a zero-order intravenous infusion (infusion duration 20–40
min). Antinociception or respiratory depression was measured
at pre-defined time points. Serial arterial blood samples were
collected at fixed time-points. 50 ml plasma was separated from
thebloodbycentrifugationandtheplasmasampleswerestored
at j20-C prior to analysis.
Measurement of Antinociception
A tail flick analgesia meter (Columbus Instruments,
Columbus, Ohio, USA) was used to determine the pain
sensitivity in the control and the drug-treated rats. Radiant
heat was applied using a shutter-controlled lamp as a heat
source focused on a spot located 6.5 to 7.5 cm from the tip of
the tail. The intensity of the beam was set at a level
producing basal latency times between 2.5 and 3.5 s. To
prevent tissue injury, the cut-off time was fixed at 10 s. A
digital response time indicator with a resolution of 0.1 s
measured the time between activation of the light beam and
the tail flick.
Measurement of Respiratory Depression
Respiratory depression was determined in unrestrained,
conscious animals using whole-body plethysmography for the
quantification of ventilation (Model PLY3223, Buxco Elec-
tronics Inc., UK). Briefly, the animals were placed in a
plethysmograph, consisting of a measurement chamber and
an integrated reference chamber to correct for atmospheric
disturbances. Both chambers were connected to a differential
pressure transducer (TRD5700, Buxco Electronics Inc., UK).
In each animal the effects of opiates and vehicle on
ventilation were assessed at an inhaled concentration of
6.5% carbon dioxide on a background of normoxia (20%
oxygen). The inhalation of the gas mixture lasted 5 min to
ensure that steady-state ventilation had been reached. Tidal
volume (VT), breathing frequency (RR) and minute ventila-
tion (Vi, where Vi=VT RR) were obtained from changes in
chamber pressure using a low-pressure differential transducer
connected to preamplifier modules (MAX2270, Buxco Elec-
tronics Inc., UK). During the experiment body temperature
was maintained at 37.5-C using heating pads. Body temper-
ature was monitored continuously by radiotelemetry (model
RPC-1, Data Sciences International, USA).
Determination of Buprenorphine and Fentanyl
Concentrations
Two different chemical assays were used for the deter-
mination of buprenorphine and fentanyl plasma concentra-
tion in rats. The details of these assays have been described
elsewhere (18). Briefly, for buprenorphine, to 50 mlp l a s m a2 5ml
internal standard (4 mg/100 ml
2H4-buprenorphine) was
added. Subsequently, 25 ml concentrated ammonia was
added and the samples were extracted by liquid/liquid
extraction with 600 ml tert.-butyl methyl ether (MTBE). The
chromatographic system consisted of an Agilent HP 1100
HPLC system (Agilent, Waldbronn, Germany) coupled to an
API 4000 LC/MS/MS system (Applied Biosystems, Darmstadt,
Germany). Chroma- tography was performed on a precolumn
(Metaguard Polaris 3m C18A 2 mm, Varian Darmstadt,
Germany) guarded Synergi 4 m Hydro-RP 80A column 75 2
mm (Phenomenex, Aschaffenburg, Germany). The lower limit
of quantification (LLOQ) was 0.047 ng/ml for buprenorphine.
The accuracy ranged from 99.4 to 102.1%. The precision,
expressed as coefficient of variation, ranged from 2.2 to 6.4%
for concentrations between 0.14 and 8.9 ng/ml.
For fentanyl, to 50 ml plasma 25 ml internal standard
(14.8 ng/ml
2H5-fentanyl) was added. After adding 10 ml
concentrated ammonia the samples were extracted by liquid/
liquid extraction with 600 ml tert.-butyl methyl ether (MTBE).
The chromatographic system consisted of an Agilent HP 1100
HPLC system (Agilent, Waldbronn, Germany) coupled to an
API 3000 LC/MS/MS system (Applied Biosystems,
Darmstadt, Germany). Chromatography was performed on a
precolumn (Metaguard Polaris 3m C18A 2 mm, Varian
Darmstadt, Germany) guarded Atlantis C18 column 3 m
100 mm 2.1 mm (Waters, Eschborn, Germany). The lower
limit of quantification (LLOQ) was 0.118 ng/ml. The accuracy
ranged from 87.0 to 96.1% and the precision from 1.9 to 4.0%
for concentrations in the range from 0.4 to 50.2 ng/ml.
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The pharmacokinetic and pharmacodynamic parameters
of fentanyl and buprenorphine were estimated using non-
linear mixed-effects modeling as implemented in the NON-
MEM software (version V, level 1.1; 25). For pharmacokinetic
analysis, a population analysis approach using the first order
conditional estimation method with h–( interaction (FOCE
interaction) was undertaken. For logistic regression pharma-
codynamic analysis, the maximum likelihood estimation
algorithm in NONMEM with the Laplacian method (FOCE)
and the likelihood option was used to estimate the probabil-
ity of a certain event occurring. All fitting procedures were
performed on an IBM-compatible computer (Pentium IV,
1,500 MHz) running under Windows XP with the Fortran
compiler Compaq Visual Fortan version 6.1. An in-house
available S-Plus 6.0 (Insightful Corp., Seattle, WA, USA)
interface to NONMEM was used for data processing and
management (including tools to perform non-parametric
bootstrap) and graphical data display. Model comparisons
were based on the objective function values in NONMEM
using the likelihood ratio test. The significance level was set
at a=0.01, which corresponds to a reduction of 6.6 U in
objective function value (OFV; c
2 distribution) to discriminate
between two nested structural models after inclusion of one
additional parameter. Furthermore, the goodness-of-fit of the
pharmacodynamic models was evaluated by simulating values
of the effectiveness and safety outcome from the raw data.
The simulations were repeated a total of a 100 times. The
proportions of observed and simulated scores were plotted
versus the 25th, 50th (median), 75th quantiles of the pooled
opioid biophase concentrations.
Pharmacokinetic Analysis
One, two and three-compartment linear models were
evaluated to characterize the time course of buprenorphine
and fentanyl concentration in plasma. The pharmacokinetic
parameters were assumed to be log-normally distributed and
therefore an exponential distribution model was used to
account for inter-individual variability. Proportional error
models were used to quantify residual error. Individual
Bayesianpharmacokinetic parameterestimatesobtainedfrom
the final population pharmacokinetic model served as input
for pharmacodynamic model to predict fentanyl and bupre-
norphine concentrations at observation scores time points
(two-stage approach). The extent of Bayesian shrinkage was
evaluated for each parameter in the final population pharma-
cokinetic models of buprenorphine and fentanyl by (26):
Shrinkage ¼ 1  
SD PKparameter
4PKparameter
ð1Þ
in which the SD is the standard deviation of the individual
estimates of h for each pharmacokinetic parameter and
WPK parameter is the estimate of the standard deviation of the
estimated population variance.
To quantify the precision of the pharmacokinetic param-
eters estimates a non-parametric bootstrap was performed.
Briefly, one thousand bootstrap replicates were generated by
sampling randomly from the original data set with replace-
ment. Subsequently, the data sets were fitted one at the time
to the final population PK model. The mean, standard error,
coefficient of variation and the lower and upper 95%
confidence intervals of the model parameter values were
calculated and compared to the typical model parameter
values from the original study.
Pharmacodynamic Data Analysis
The effectiveness (antinociception) and safety (respira-
tory depression) variable were modeled as dichotomous
category variables. The following transformation statements
were applied to convert the continuous data into logical two-
valued data:
– If antinociceptive effect Q 10 s, then observation score
is 1 (a yes response; complete antinociception) else 0 (a no
response; no antinociception)
– If respiratory depressant effect Q 50%, then observa-
tion score is 1 (a yes response; severe respiratory depression)
else 0 (a no response; no respiratory depression)
Logistic regression analysis was performed to determine
the relationship between opioid concentration at the biophase
(Ce) and its respective antinociceptive or respiratory depres-
sant effect in rats. The opioid biophase concentration was
predicted using a standard effect–compartment model (27):
dCe
dt
¼ ke0   Cp   Ce

ð2Þ
in which Cp represents the opioid plasma concentration, Ce the
opioid concentration at the biophase and ke0 the first-order
rate constant for biophase distribution.
A linear logit model was fitted to relate the probability
of having complete antinociception or respiratory depression
to drug exposure at the biophase:
P Yij¼1 ðÞ ¼
1
1 þ e  fC e ðÞ ðÞ ð3Þ
The logit transformation ensures that the probability P
will fall between 0 and 1, f(Ce) is a linear function of drug
exposure at the biophase:
fC e ðÞ ¼ ! þ   Ce ðÞ ð 4Þ
in which a and b are the intercept and slope of the regression
equation and Ce is the drug biophase concentration. Incor-
poration of individual random effects, h with mean zero and
variancew
2, was tried by assuming exponential distributions for
the regression parameters (a and b). For each concentration–
effect relationship, the odds ratio was calculated using the
exponent of the estimated slope b (e
b). The odds ratio is
defined as the change in the estimated odds of the outcome
when the biophase concentration increases by 1 U. Bootstrap
analysis was performed with the final logistic regression
pharmacodynamic models to construct the 95% confidence
intervals of the calculated odds ratios.
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to evaluate the effectiveness/safety balance of buprenorphine
andfentanylasa function of drugexposure.The utility function
was determined by the sum of the weighted probabilities of an
efficacious and safe outcome. The effectiveness and safety
variables were weighted equally. For the desirable antinoci-
ceptive effect the weight factor was positive and for respiratory
depression the factor was negative. The effectiveness/safety
balance,characterizedbytheutilityfunctionwasthusexpressed
as Pr{effectiveness}–Pr{safety}, where Pr{x} is the probability of
outcome x (28). A negative value of the utility function
indicates that the respiratory depressant effect dominates and
a positive value suggests that the desired antinociceptive effect
dominates.
RESULTS
Pharmacokinetics
A three-compartment model adequately described the
time course of the concentration profiles of buprenorphine
after intravenous administration in rats. Inter-individual vari-
abilitywasestimatedforallpharmacokineticparametersexcept
for Q3. The parameter estimates with their corresponding
standard error (SE) are summarized in Table I. For fentanyl, a
two-compartment pharmacokinetic model with inter-animal
variability on all pharmacokinetic parameters best described
the disposition in plasma. The parameter estimates with their
corresponding standard error (SE) are summarized in Table II.
Estimates of shrinkage were low and ranged from 0.02 (Cl) to
0.19 (V1) for buprenorphine and from 0.03 (Cl) to 0.12 (V2)f o r
fentanyl, suggesting that the individual pharmacokinetic
parameter estimates of buprenorphine and fentanyl are robust.
For comparison, values of shrinkage close to 1 indicate poor
individual estimates of the pharmacokinetic parameters. The
goodness-of-fit plots (predicted/individual predicted versus
observed concentrations, population predicted concentrations
versus weighted residuals for population predictions (WRES)
and time versus weighted residuals for population predictions
(Figs. 1 and 2) indicated that the pharmacokinetic models
adequately described the concentrations of buprenorphine and
fentanyl. Finally, bootstrap analysis showed that the 95% CI of
the pharmacokinetic parameter estimates and their random
effect variables, except for w
2V2 of buprenorphine, did not
overlap their respective null values (Tables I and II).
Pharmacodynamics
After transformation of the continuous data into cate-
gories, 615 (35 animals) and 444 (32 animals) observations of
response/no response scores to complete antinociception and
severe respiratory depression, respectively, were available for
analysis of the pharmacodynamic effect of buprenorphine in
rats. For fentanyl, 486 (40 animals) and 216 (32 animals)
observations were included for pharmacodynamic analysis for
the antinociceptive and respiratory depressant effect, respec-
tively. For the antinociceptive effect of buprenorphine, the
values of parameters characterizing the linear logistic re-
gression model were j13.3 (95% CI, j16.08 to j10.52) for
the intercept a and 3.35 (95% CI, 2.59–4.11) for the slope b
of the regression equation. The odds ratio of complete anti-
nociception occurring is equal to e
3.35, corresponding to an
odds ratio of 28.5 (95% CI, 6.9–50.1). The odds ratio is
statistically different from 1, indicating that the probability of
complete antinociception occurring is dependent on the
buprenorphine plasma concentration. Inter-animal variability,
w
2 was estimated for b and was 0.130 (95% CI, 0.08–0.181).
For respiratory depression, the typical values estimates for
Table I. Parameter Estimates (95% CI) for the Final Population Pharmacokinetic Model of Buprenorphine
Original Data 1,000 Bootstrap Replicates
Typical Estimate Inter-Animal Variability w
2 Typical Estimate Inter-Animal Variability w
2
Cl (ml/min) 18 (16.3–19.7) 0.128 (0.108–0.148) 18 (16.1–19.9) 0.125 (0.086–0.164)
V1 (ml) 110 (77–142) 0.936 (0.348–1.52) 108 (65–150) 0.914 (0.267–1.56)
V2 (ml) 370 (312–428) 0.274 (0.117–0.431) 400 (320–480) 0.353 (j0.041–0.745)
V3 (ml) 1,200 (1,009–1,391) 0.337 (0.200–0.474) 1,181 (907–1,455) 0.239 (0.063–0.415)
Q2 (ml/min) 30 (26–34) – 30.3 (26–35) –
Q3 (ml/min) 11 (9.6–12.4) 0.172 (0.094–0.250) 10.2 (7.8–12.6) 0.128 (j0.048–0.304)
Proportional error (%) 0.032 (0.022–0.042) 0.033 (0.021–0.045)
Table II. Parameter Estimates (95% CI) for the Final Population Pharmacokinetic Model of Fentanyl
Original Data 1,000 Bootstrap Replicates
Typical Estimate Inter-Animal Variability w
2 Typical Estimate Inter-Animal Variability w
2
Cl (ml/min) 17.0 (16.9–18.1) 0.060 (0.040–0.080) 16.6 (15.7–17.4) 0.058 (0.038–0.078)
V1 (ml) 250 (218–282) 0.227 (0.129–0.325) 255 (222–287) 0.224 (0.126–0.322)
V2 (ml) 440 (404–476) 0.080 (0.041–0.119) 444 (409–479) 0.077 (0.039–0.116)
Q (ml/min) 9.7 (8.3–11.1) 0.224 (0.126–0.312) 9.7 (8.3–11.1) 0.216 (0.118–0.314)
Proportional error (%) 0.034 (0.0240.044) 0.034 (0.024–0.044)
186 Yassen et al.the intercept (a) and slope (b) of the regression equation
were j5.22 (95% CI, j6.54 to j3.90) and 0.744 (95% CI,
0.083–1.405), respectively. The odds ratio of severe respiratory
depressionoccurringisequaltoe
0.774, corresponding to an odds
ratio of 2.10 (95% CI, 0.71–3.49). The odds ratio is not
statistically different from 1, indicating that the probability of
observing severe respiratory depression does not change
within the studied buprenorphine biophase concentration
range. Inter-animal variability, w
2 was estimated for b and
was 1.82 (95% CI, 0.57–3.07). The odds ratio estimates of
buprenorphine obtained from the logistic regression analysis
are shown in Table III. Goodness-of-fit was evaluated by the
objective function value (OFV) and by simulating the raw data
from the final pharmacodynamic logistic regression model.
The proportion of the simulated values of the outcome scores
for buprenorphine agreed well with the observed scores as can
be seen in Fig. 3. For fentanyl, the values of the parameters a
and b were j8.77 (95% CI, j11.49 to j6.05) and 1.11 (95%
CI, 0.726–1.494), respectively. The odds ratio for the
antinociceptive effect was 3.03 (95% CI, 1.87–4.21) and was
significantly different from 1 (p<0.05). Inter-animal variability,
w
2 was estimated for b and was 0.0839 (95% CI, j0.01–0.177).
For the respiratory depressant effect the values of the logistic
regression parameters a and b were j5.86 (95% CI, j8.17
to j3.55) and 0.930 (95% CI, 0.430–1.430). The odds ratio for
the occurrence of severe respiratory depression was 2.54 (95%
CI, 1.26 to 3.82). Inter-animal variability, w
2 was estimated for
b and was 0.193 (95% CI, 0.085 to 0.300). The odds ratio
estimates of fentanyl obtained from the logistic regression
analysis are shown in Table III. The goodness-of-fit plots for
fentanyl are shown in Fig. 4. In the final analysis, the half-time
of biophase distribution was included in the final model.
Fig. 1. Goodness-of-fit plots for the final population pharmacokinetic model of buprenorphine.
187 Effectiveness and Safety of Buprenorphine and FentanylAlthough its value is not significantly different from zero, its
inclusion significantly improved the fits as judged by a
significant drop (>6.6 points) in objective function value.
Finally, a therapeutic overall utility function was con-
structed for the effectiveness/safety balance of buprenor-
phine and fentanyl. In Fig. 5, it is shown that in the measured
concentration range, the utility function of buprenorphine is
positive. This indicates that the antinociceptive effectiveness
of buprenorphine exceeds the risk of the occurrence of
respiratory depression. For fentanyl, the utility function is
negative in the measured concentration range, indicating that
fentanyl produced more respiratory depression than bupre-
norphine. At relatively high concentrations the utility func-
tion is close to zero for fentanyl and buprenorphine,
suggesting that the probability of a desired and side-effect
are equal.
DISCUSSION
Population PK–PD models of buprenorphine and fen-
tanyl, administered intravenously with plasma concentration
as the exposure variable and the response to complete
antinociception or severe respiratory depression as a binary
outcome variable were developed to evaluate the effective-
ness and safety of these opiates in rats.
The assignment of observation scores 0 and 1 to the
pharmacodynamic safety outcome to indicate Bno^ or
Bsevere^ respiratory depression, respectively, was arbitrarily
chosen and is a matter of discussion. Despite its severity,
there is no clear and unifying definition for respiratory
depression in the literature (29). Partly this is related to the
difficulty of measuring opiate-induced respiratory depression
in a reliable and strictly quantitative manner. Although
Fig. 2. Goodness-of-fit plots for the final population pharmacokinetic model of fentanyl.
188 Yassen et al.various biomarkers for respiratory depression have been
proposed, including the measurement of respiratory rate (30)
and arterial PaCO2 values (31), many of these biomarkers are
rather subjective and only provide a qualitative assessment of
respiratory depression (32). Furthermore, many of the tech-
niques used to characterize respiratory depression, may well
underestimate the respiratory depressant effect of opiates (11).
In contrast, minute ventilation measured by whole-body
plethysmography or the dynamic end-tidal forcing technique
has been shown to be an objective, reproducible and sensitive
measure of the respiratory effects of opiates (33). More
Fig. 3. Goodness-of-fit plots of the logistic regression model for buprenorphine. Observed (left panels) and simulated (right panels) values of
the buprenorphine_s effectiveness (upper panels) and safety (lower panels) outcome for the different concentration categories. Simulations
were repeated in total a 100 times. The concentrations were divided in the following categories (scores at Ce=0, between 0 and 25th quantiles,
25th–50th quantiles, 50th–75th quantiles, >75th quantiles; h score=0 and v score=1).
Table III. Odds Ratio and Half-Time of Biophase Distribution
(T1/2,ke0) Estimates (95% CI) Obtained From the Logistic Regression
Pharmacodynamic Analysis for Buprenorphine and Fentanyl
T1/2,ke0 (min) Buprenorphine Fentanyl
Antinociception 86.4 (71.3–101.5) 6.08 (4.43–7.73)
Respiratory depression 109 (49–169) 1.97 (j0.32–4.26)
Odds ratio
Antinociception 28.5 (6.9–50.1) 3.03 (1.87–4.21)
Respiratory depression 2.10 (0.71–3.49) 2.54 (1.26–3.82)
189 Effectiveness and Safety of Buprenorphine and Fentanylimportantly, minute ventilation as a biomarker of respiratory
depression has been shown to reflect the functioning of various
opiates at the m-opioid receptor in a strictly quantitative
manner (15,16,34). Since measurement of minute ventilation
allows for a quantitative assessment of respiratory depression,
we defined respiratory depression as a decrease in ventilation
of more than 50% relative to baseline. For the antinociceptive
effect, reaching the cut-off tail flick latency time is frequently
used to indicate that complete antinociception is reached (35).
In the present investigation, therefore, the same definition was
used to indicate complete antinociception.
PK–PD analysis revealed marked difference in the
kinetics of onset and offset for buprenorphine versus
fentanyl. The biophase distribution of buprenorphine was
significantly slower than for fentanyl. On the basis of the
physico-chemical properties (buprenorphine being more
lipophilic than fentanyl; 16) it can be expected that bupre-
norphine displays slower biophase distribution. Furthermore,
buprenorphine_s slow receptor association/dissociation kinet-
ics contributes to the delay in the onset of buprenorphine_s
analgesic and respiratory depressant effect. Previously it was
shown that the delay in buprenorphine_s antinociceptive and
Fig. 4. Goodness-of-fit plots of the logistic regression model for fentanyl. Observed (left panels) and simulated (right panels) values of the
buprenorphine_s effectiveness (upper panels) and safety (lower panels) outcome for the different concentration categories. Simulations were
repeated in total a 100 times. The concentrations were divided in the following categories (scores at Ce=0, between 0 and 25th quantiles, 25th–
50th quantiles, 50th–75th quantiles, >75th quantiles; h score=0 and v score=1).
190 Yassen et al.respiratory depressant effect is mainly caused by biophase
distribution rather than slow receptor association/dissociation
kinetics (15,18).
Beside the kinetics of the opioid action, PK–PD analysis
yielded important information on the effectiveness and safety
outcome of fentanyl and buprenorphine. The odds ratios
which had been calculated for the estimated probability of a
complete antinociceptive or severe respiratory depressant
event can be used as a measure of pharmacological effect size.
For fentanyl, the calculated odds ratios for the antinociceptive
and respiratory depressant effect were 3.03 (95% CI, 1.87–4.21)
and 2.54 (95% CI, 1.26–3.82), respectively, suggesting that
increasing the fentanyl concentration with 1 ng/ml, there is a
3.03and2.54greaterchanceofhavingcompleteantinociception
or respiratory depression, respectively. In terms of probabilities
rather than changes in odds, the estimated risk of severe
respiratory depression increased from 10.5 to 22.9% when the
concentration was increased from 4 to 5 ng/ml. In addition, the
probability of achieving complete antinociception increased
from 0.4 to 1.2%. The estimated values of the odds ratio for
antinociception (3.03) and respiratory depression (2.54) are
nearly identical and suggest that fentanyl displays almost no in
vivo tissue selectivity. Accordingly, the ratio of the two OR_s
(antinociception/respiratory depression) is equal to 1.20
(3.03:2.54) for fentanyl. This ratio can be used as a safety index
and suggests that fentanyl displays no selectivity of action.
For buprenorphine, the odds ratios were 28.5 (95% CI,
6.9–50.1) and 2.10 (95% CI, 0.71–3.49) for the antinociceptive
and respiratory depressant effect, respectively. The large
difference in calculated odds ratio_s for the antinociceptive and
respiratory depressant effect indicates that buprenorphine_s
displaysavaryingdegreeoftissueselectivity.Thesafetyindexis
equal to 13.54 (28.5:2.10) and suggests a favorable selectivity of
action. This provides further evidence, in contrast to fentanyl,
for the relative safety of buprenorphine when administered in
therapeutic analgesicdoses.In various receptor binding studies,
buprenorphine has been shown to act as a partial agonist at the
m-opioid receptor (17). Partial agonists typically require
complete receptor occupancy for maximal response (36). For
the respiratory depressant effect, the in vitro partial agonist
activity correlates well its in vivo respiratory depressant effect,
characterized by ceiling at higher concentrations (37,38).
Buprenorphine and fentanyl are m-opioid agonists with
distinct pharmacological properties. Since fentanyl behaves
as full agonist its in vivo potency for respiratory depression
and antinociception are determined byboth the affinity and the
intrinsic efficacy at the m-opioid receptor In contrast, for the
partial agonist buprenorphine the in vivo potency is deter-
mined solely by its affinity for the m-opioid receptor (39).
These differences between efficacy- and affinity-driven ago-
nism may have major implications for the therapeutic utility of
opioids. Therapeutic utility is a measure of the effectiveness of
drugs. Given this measure, one can speak of increasing or
decreasing utility and thereby explain pharmacological behav-
ior of a drug in terms of attempts to optimize pharmacother-
apy. As recently discussed by Cullberg et al. (2005; 28)t h e
most adequate representation of drug_s effectiveness/safety
balances with a utility function remains a matter of debate. In
the present study, the therapeutic utility function is equal to
the sum of the weighted probabilities of an effective (anti-
nociception) and a safety (respiratory depression) outcome.
The effect measures, antinociception and respiratory depres-
sion, were weighted equally and this seems justified, given that
respiratory depression is a potentially life-threatening side-
effect with an acute time course. Furthermore, for the
construction of the utility function the continuous antinoci-
ceptive and respiratory depressant continuous effect variables
were transformed into dichotomous data. This type of data
transformation will entail loss of pharmacodynamic informa-
tion. Especially the kinetics of onset and offset of the opioids
effect can be estimated less accurately. However, the kinetics
of onset and offset of buprenorphine_s antinociceptive and
respiratory depressant effect have been characterized previous-
ly (15,18). Using a continuous measure of respiratory depres-
sionandantinociceptionone can still construct utilityfunctions.
However, using this approach it requires a clear definition of an
Emax value for respiratory depression and antinociception. For
antinociception no Emax could be identified in the studied dose
range. As a consequence the therapeutic utility of buprenor-
phine can be overestimated when the continuous variables
were used for the construction of a utility function. Therefore,
the continuous data were transformed into dichotomous data
enabling the definition of clear cut-offs.
An intriguing question remains whether the calculated
safety margins and therapeutic utilities of buprenorphine and
fentanyl are similar in rats and humans. The calculated
therapeutic utility is determined by the opioid_s affinity and
intrinsiceffectivenessatthem-opioidreceptor.Intheory,these
two pharmacological terms are drug-specific parameters, both
of which are expected to be similar between man and rat for
the m-opioid receptor (high degree of receptor homology).
Recently, it was shown that indeed the drug-specific param-
eters of buprenorphine are similar in rats and humans for both
the antinociceptive and respiratory depressant effect (40). It is
therefore advocated that the calculated therapeutic utility for
Fig. 5. Estimated therapeutic utility function of buprenorphine
(dashed line) or fentanyl (solid line) treatment as a function of its
respective biophase exposure. The therapeutic utility function is
defined as probability of antinociception—probability of respiratory
depression.
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in rats and humans. Since fentanyl is a full m-opioid agonist
for both antinociception and respiratory depression, produc-
ing maximal pharmacological responses in rats and humans,
it is expected that the therapeutic utility of fentanyl is not
significantly different between these two species. On the
basis of the calculated therapeutic utility of fentanyl in rats it
can be concluded that fentanyl has a narrow therapeutic
window in man (low safety index) requiring fentanyl to be
administered cautiously to patients. In fact, a series of recent
case-reports on fentanyl-induced severe respiratory depres-
sion and death in patients confirm fentanyl_s low safety
margin underscoring the importance of careful dose titration
of high-effectiveness opioids like fentanyl (41). For bupre-
norphine, the utility function also approaches zero at relatively
high concentration upon acute exposure. It should be noted,
however, that thisisinherenttothe definition of the occurrence
of respiratory depression in the present study. Previously it has
been shown that the maximum respiratory depressant effect of
buprenorphine is approximately 48 to 55% versus 90 to 100%
for fentanyl, suggesting that although the utility function
becomes zero, the absolute degree of respiratory depression is
less for buprenorphine than for fentanyl. Furthermore, the
calculated safety index indicates that buprenorphine has a
wider therapeutic window, allowing for the administration of
relatively high doses of buprenorphine. Reported safety
incidences related to buprenorphine are low and deaths due
to buprenorphine misuse are rare. This makes buprenorphine a
particularly safe opioid with an increased margin of safety (42).
As evaluation of drug safety becomes increasingly more
important in contemporary drug development, there will be a
clear shift towards the application of PK/PD modeling to
predict drug safety outcomes. As more mechanistic bio-
markers become available to assess drug safety, this gives rise
to the development of more sophisticated and mechanistic
PK/PD models to assess drug effectiveness/safety balances.
Clearly, this also influences the selection and structure of
therapeutic utility functions to assess the effectiveness/safety
balances of drugs under development. To this end, utility
functionwillbecomelessdescriptiveandmorepredictive.Also,
the potential utility of mechanistic biomarkers to facilitate drug
development may lead to better techniques to assess the safety
in humans more in line with those used in animals, yielding
more accurate animal to human effectiveness/safety extrapola-
tion in an early stage of drug development.
CONCLUSION
Logistic regression pharmacodynamic models were de-
veloped to predict the safety and effectiveness outcome of
buprenorphine and fentanyl in rats. Buprenorphine has been
shown to display ceiling in respiratory effects but not in
analgesia upon acute administration. This explains the
relatively high safety index and indicates that the ceiling
respiratory effect contributes to the safety profile of bupre-
norphine. For fentanyl a narrow therapeutic window has been
observed, complicating fentanyl dose titration to the optimum
analgesic effect without the occurrence of severe respiratory
depression. The modeling of the effectiveness/safety balances
is a first quantitative assessment of the effectiveness/safety of
opiates and these results are in good agreement with the
general perception on the safety issues of buprenorphine and
fentanyl, underscoring the importance of the development of
PK–PD models to quantitatively assess the rationality of
pharmacotherapeutic utilities.
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